Pfizer Investor Presentation — October 2018

Document content

Earnings Teleconference

October 30, 2018 Introduction

Senior Vice President,

Third Quarter 2018 Earnings Third Quarter 2018 Earnings

3 Forward -Looking Statements and

Non-GAAP Financial Information

 Our discussions during this conference call will include forward- looking statements about, among other things, our

anticipated future operating and financial performance, business plans and prospects, in- line products and product

candidates, including anticipated regulatory submissions, data read- outs, study starts, approvals, performance, timing of

exclusivity and potential benefits of Pfizer's products and product candidates, strategic reviews, capital allocation, business-

development plans, the benefits expected from our plans to organize our commercial operations into three businesses effective at the beginning of the company's 2019 fiscal year, the benefits expected from our acquisitions and other business development activities, our ability to successfully capitalize on growth opportunities, manufacturing and product supply and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year ended December 31, 2017 and in our

subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8- K, all of which are

filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com

looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.